Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
IHC - Frozen, Western blot, Flow Cytometry, Functional Assay
Mouse Monoclonal [clone MEM-43] (IgG2a) to Human CD59
Immunofluorescence, Flow Cytometry
Human (tested or 100% immunogen sequence identity)
IgG2a Monoclonal [MEM-43]
Protein A purified
Immunofluorescence (5 µg/ml)
Flow Cytometry (5 µg/ml)
Specificity and Use
CD59 antibody was raised against thymocytes and T lymphocytes.
Reacts with well defined epitope (W40, R-53) on CD59 (Protectin), an 18-20 kD glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on all hematopoietic cells; it is widely present on cells in all tissues.
Biotinylated antibody is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working dilution is 5 microgram/ml. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determin The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.
PBS, 15 mM sodium azide, approx., pH 7.4.
Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles.
CD59 is a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation.